Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing...
The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation. Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events. The aim of this registry,...
Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive medication, patients undergoing radiofrequency renal denervation have seen significant improved control of blood pressure, with relevant clinical impact. One of the outcomes we look at in chronic diseases such as hypertension and diabetes is time in target range...
Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis. This study included 45 patients with severe AR. Primary end...
TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges is patients with a small annulus. When using self-expanding valves, supra-annular implantation is recommended. However, at present, we only have retrospective, observational studies, not large enough. The LYTEN Trial is a randomized study in patients presenting failed bioprosthetic...
The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5 times more deadly, has negatively affected quality of life and has increased healthcare costs. The ASTRO TAVI registry included 14 centers and 16615 TAVR procedures between 2006 y 2021. In this period, there were 484 neurological events within...
This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram. Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low. 60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR). 6.1% of patients were in stage 0 (no damage), 14.5% were...
Edge-to-edge treatment of the mitral valve is currently a valid alternative to surgery in cases of mitral regurgitation. Different studies have taken residual mitral regurgitation as a parameter of success, but little research has been conducted on the residual gradient once the procedure has been completed. What has been published is that a mean gradient...
Once more, the Latin American Society of Interventional Cardiology (SOLACI) will attend two of the most important annual meetings in the field: the EuroPCR 2022 and the SCAI 2022 Scientific Sessions. The society will take part in with 2 challenging joint sessions to shar the Latin American reality in different areas of interest within the...
Mitral valve prolapse is the most frequent cause of mitral valve regurgitation and is associated to hospitalization for cardiac failure and mortality. At present, the preferred treatment for operable patients is mitral valve surgical repair. Transcatheter edge to edge repair (TEER) has shown great benefit patients at high surgical risk; however, it has not been...